Published in final edited form as:

J Mol Med (Berl). 2013 June ; 91(6): 749–758. doi:10.1007/s00109-013-0996-2.

Dichloroacetate Reverses the Hypoxic Adaptation to Bevacizumab and Enhances its Antitumor Effects in Mouse Xenografts

Krishnan Kumar^{1,a}, Simon Wigfield^{4,a}, Harriet E. Gee^{4,5}, Cecilia M. Devlin¹, Dean Singleton⁴, Ji-Liang Li⁴, Francesca Buffa⁴, Melanie Huffman¹, Anthony L. Sinn³, Jayne Silver³, Helen Turley⁴, Russell Leek⁴, Adrian L Harris^{4,b,c}, and Mircea Ivan^{1,2,b,c}

¹Dept of Medicine, Indiana University, Indianapolis, IN, 46202, USA

²Dept of Immunology and Microbiology, Indiana University, Indianapolis, IN, 46202, USA

³In Vivo Therapeutics Core, Indiana University Simon Cancer Center, Indianapolis, IN, 46202, USA

⁴Department of Oncology, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DS, UK

⁵Department of Radiation Oncology, Sydney Cancer Centre, Royal Prince Alfred Hospital, Camperdown, NSW, 2050, Australia

Abstract

Inhibition of vascular endothelial growth factor (VEGF) increases response rates to chemotherapy and progression-free survival in glioblastoma. However, resistance invariably occurs, prompting the urgent need for identification of synergizing agents. One possible strategy is to understand tumor adaptation to microenvironmental changes induced by antiangiogenic drugs, and test agents that exploit this process. We used an *in vivo* glioblastoma-derived xenograft model of tumor escape in presence of continuous treatment with Bevacizumab. U87-MG or U118-MG cells were subcutaneously implanted into either BALB/c SCID or athymic nude mice. Bevacizumab was given by intraperitoneal injection every 3 days (2.5mg/kg/dose) and/or dichloroacetate (DCA) was administered by oral gavage twice daily (50mg/kg/dose) when tumor volumes reached 0.3cm³, and continued until tumors reached approximately 1.5–2.0cm³. Microarray analysis of resistant U87 tumors revealed coordinated changes at the level of metabolic genes, in particular a widening gap between glycolysis and mitochondrial respiration. There was a highly significant difference between U87-MG implanted athymic nude mice 1 week after drug treatment. By 2 weeks of treatment, Bevacizumab and DCA together dramatically blocked tumor growth compared to either drug alone. Similar results were seen in athymic nude mice implanted with U118-MG cells. We demonstrate for the first time that reversal of the Bevacizumab-induced shift in metabolism using DCA is detrimental to neoplastic growth *in vivo*. As DCA is viewed as a promising agent

To whom correspondence may be addressed. Mircea Ivan, Departments of Medicine, Immunology and Microbiology, Indiana University, 980W. Walnut Street, Room C225, Indianapolis, IN 46202. Tel 317-2740322. Fax 317-2740396. mivan@iupui.edu, Adrian L. Harris, Department of Oncology, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DS, UK. Tel +44 (0)1865 222457. Fax +44 (0)1865 222431. adrian.harris@oncology.ox.ac.uk.

^aEqual first authors

^bEqual senior authors

Author's Contributions Conception and design: M.I., A.L.H. Acquisition of data: K.K., S.W., H.E.G., H.T., J.L., J.S., A.L.S., R.L., D.S., C.M.D., M.H. Analysis and interpretation of data: M.I., A.L.H. Writing, review, and/or revision of the manuscript: M.I., A.L.H. Administrative, technical, or material support: F.B. Study supervision: M.I., A.L.H.

Disclosure of Potential Conflicts of Interest No potential conflicts of interest to declare.

targeting tumor metabolism, our data establish timely proof of concept that combining it with antiangiogenic therapy represents a potent antineoplastic strategy.

Keywords

Dichloroacetate; hypoxia; Bevacizumab; oxidative phosphorylation; glycolysis

INTRODUCTION

Molecular therapies targeting neo-angiogenesis, and in particular vascular endothelial growth factor (VEGF), have shown antitumor activity in a variety of clinical contexts [1]. Glioblastoma (GBM) is a highly vascularized and lethal primary brain tumor, with median survival of approximately 12–14 months, and therefore represents an important target for anti-angiogenic drugs [2]. Bevacizumab, a humanized anti-VEGF antibody, is currently approved by the Food and Drug Administration as second-line treatment of GBM, and ongoing clinical trials aim at assessing its potential as a first-line agent [3]. However, as VEGF blockade prolongs progression – free survival but not overall survival, it is imperative to identify strategies that increase its impact and delay the onset of resistance [4]. For example, limited progress has been achieved in combination with irinotecan, however no impact on overall survival could be demonstrated [5]. One major limitation in developing synergistic combinations centered on anti-VEGF agents is lack of robust clinical data, as tumors that are becoming resistant to these agents are not routinely available for further analyses. Moreover, the cellular and molecular consequences of anti-VEGF treatment are still insufficiently understood. Detailed information at the molecular level on how Bevacizumab affects GBM during an extended timeframe is not only essential to our understanding of tumor adaptive responses and subsequent treatment failure, but also to the development of rational combination therapies.

We therefore sought to determine the tumor response to Bevacizumab at the phenotypic and molecular level in xenograft models derived from GBM cell lines. By extending the models until eventual therapeutic failure despite continuous Bevacizumab treatment, we aimed to capture the tumor adaptive programs and the corresponding rewiring of the molecular pathways using microarray analysis. We hypothesized that the core mechanisms of resistance would be reflected in alteration of these pathways, and small molecules which interfere with these processes represent realistic candidates to increase the potency of Bevacizumab. Bioinformatic analysis revealed that resistant tumors exhibit a strong Hypoxia-inducible factor (HIF) signature and shift from mitochondrial respiration to glycolysis. Reactivation of mitochondrial respiration with the orphan drug dichloroacetate (DCA) enhances the transient effect of Bevacizumab, in contrast to the lack of additive effect of 2-deoxyglucose (2-DG), which primarily targets glycolysis. Our data provide insights into the plasticity of tumor metabolism in response to therapeutic challenges, and that suggests novel opportunities for synergistic interventions.

MATERIALS AND METHODS

In Vivo Tumorigenicity

All protocols were carried out under Indiana University Institutional Animal Care and Use Committee (IACUC), and UK Home Office approved protocols and regulations. 10^7 U87-MG cells (purchased from ATCC) were implanted into 6- to 8-week-old female BALB/c SCID mice (Harlan Sprague Dawley, Inc.) subcutaneously, as 100 μ L cell suspensions with an equal volume of Matrigel (BD Bioscience). Tumors were measured twice a week with a caliper, and volumes were calculated using the formula: length $\times$ width $\times$ height $\times$ 0.52. Once

the tumor volume reached 150 mm³, mice were randomized into two groups with starting cohort sizes of 5 mice per group and treatment of Bevacizumab (Roche) injected intraperitoneally every 3 days at a dose of 10 mg/kg or saline control begun. Treatment was continued until tumors grew to approximately a volume of 600–800mm³ at which point the mice were euthanized and tumors were surgically excised quickly. For the athymic nude mice xenografts models, either U87-MG cells were implanted as above into 4–8 week old female mice (Harlan Laboratories, Indianapolis, IN, USA), or 7x10⁶ U118-MG cells (purchased from ATCC) were grafted. Tumor fragments were either processed by formalin fixation before paraffin embedding for IHC, or frozen for later RNA extraction, as described previously [6].

Drug delivery protocols for combination studies

DCA was administered by oral gavage twice daily at 50mg/kg/dose in sterile water (vehicle control was sterile water). This dose was based on published reports and allometric scaling. Thus, 100mg/kg mouse/day translates into approximately 13mg/kg in humans (<http://home.fuse.net/clymer/minor/allometry.html>), which is consistent with the doses used in clinical settings. Bevacizumab was given intraperitoneally at a concentration of 2.5 mg/kg/dose (U87-MG) or 2.0 mg/kg/dose (U118-MG). Treatment was continued until tumors grew to approximately 20mm diameter at which point the mice were euthanized and tumors quickly excised. 2-deoxyglucose (Sigma, 500mg/kg) was delivered via intraperitoneal injection daily.

The details of Cell Culture, Gene Array Analysis, Histological Analysis and Immunohistochemistry, DCA treated spheroids, and RNA isolation and Quantitative RT-PCR (QPCR) analysis are described in Supplementary Electronic Material.

Statistical analysis

Statistical significance of observed differences among different experimental groups was calculated using a two-tailed t-test. P-values < 0.05 were considered to be statistically significant.

RESULTS

Establishment of the Bevacizumab-resistance tumor model

U87-MG cell suspensions were subcutaneously injected into the right flank of SCID mice. Treatment with Bevacizumab (intraperitoneal injection of 10mg BVC/kg every 3 days) was initiated when tumors averaged 100–200mm³. Divergence between the treated and non-treated cohorts was evident one week later, and at approximately day 40 complete resistance to Bevacizumab was achieved (Fig. 1). Tumors were excised separately for controls and treated cohorts at time points when their average growth rates and sizes were similar. An analogous response (i.e. initial response followed by resistance) was observed using a submaximal dose of Bevacizumab (2.5mg/kg; every 3 days by intraperitoneal injection) in athymic nude mice. This will be described in detail as part of the combination studies below. By performing immunohistochemistry for standard vascular markers (CD31 and CD34) followed by microvessel density counting, we confirmed that resistant tumors exhibit a significantly sparser vasculature (Fig. 1). Therefore therapeutic resistance does not appear to be primarily related to renewed vascularisation due to a switch to alternative angiogenic growth factors, as shown in other models of Bevacizumab resistance [7]. Expression of HIF-1, as well as of Carbonic Anhydrase IX (CA9), a robust HIF target and well-established marker of hypoxia, were dramatically increased in the resistant tumors, indicating that their growth continued in a significantly more oxygen-depleted environment consistent with data reported by Rapisarda et al. [8].

Molecular characterization of Bevacizumab-resistance model

In order to gain a comprehensive understanding of the molecular processes that are associated with, and potentially critical for the resistance process, total RNA from treated and non-treated tumors was subjected to expression analysis using HGU133plus2 Affymetrix arrays. The full data set for the Affymetrix array expression analysis is available at <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE37956>. A central theme in the Bevacizumab-resistant tumors was the coordinated activation of the HIF-driven transcription program (Fig. 2). A large proportion of HIF targets exhibited coordinated upregulation, in most cases with more than one array probe. Notably, glycolytic HIF targets including Aldolases A and C (ALDOA, ALDOC), Triose Phosphate Isomerase 1 (TPI1), and 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), as well as the inducible glucose transporters GLUT1/SLC2A1 and GLUT3/SLC2A3 were robustly induced, pointing to an increased reliance on glycolytic utilization of glucose. In contrast, a significant repression in Bevacizumab-resistant tumors was seen at the level of pyruvate dehydrogenase (PDH) alpha 1 and beta genes, that govern the entry of pyruvate into the tricarboxylic acid (TCA) cycle [9]. PDH activity is inhibited by phosphorylation by pyruvate dehydrogenase kinases (PDK). PDK1 and PDK3 isoforms, which are well documented HIF targets [10–12], were strongly upregulated in the Bevacizumab-resistant tumors, further supporting a biochemical shift away from oxidative phosphorylation (OXPHOS) (Fig. 2). Arguably the most striking gene expression change in Bevacizumab-resistant tumors was the global downregulation of mitochondrial metabolism genes, in particular members of all five mitochondrial OXPHOS complexes (Fig. 2). Finally, several components of the TCA cycle, including Fumarate Hydratase (FH) and Succinate Dehydrogenase (SDH) were downregulated (Fig. 2), which may contribute to tumor growth as they also function as tumor suppressors [13].

KEGG pathway analysis confirmed that energy metabolism represented one of the dominant changes associated with the Bevacizumab-resistant tumors. Thus, glycolytic genes were most abundant among the upregulated genes, together with genes belonging to fructose and mannose metabolism, pentose phosphate pathway, amino sugar and nucleotide sugar metabolism and inositol phosphate metabolism (Supplementary Table S1A). The hypergeometric and corrected hypergeometric p-values were lower than 0.01 for all these pathways. Conversely, among the downregulated genes, OXPHOS was the top repressed pathway, with p-values lower than 1.00E-28, with pyruvate metabolism and TCA cycle also exhibiting very highly significant repression (Supplementary Table S1B). An additional signature observed in the Bevacizumab-resistant tumors was increased endoplasmic reticulum (ER) stress and Unfolded Protein Response (UPR). In particular, the key mediators of these responses ATF4, 5, 6 and DDIT3/CHOP were all strongly overexpressed (Supplementary Table S2), consistent with our previous observations that more severe hypoxia developing during the course of anti-angiogenic therapy activates non-HIF pathways [14].

In vitro effects of chronic hypoxia on mitochondrial OXPHOS gene expression

To investigate whether hypoxia represents the primary cause of the downregulation of mitochondrial respiration and Krebs cycle genes, we undertook a comprehensive *in vitro* survey of low oxygen effects in U87 cells. Interestingly, several OXPHOS genes and Krebs cycle components that were found downregulated in the arrays, also responded by downregulation in hypoxia, including ATP5A1, ATP5G3, NDUF9, FH and MDH1 (Fig. 3). MRPL36 and MRPS11, two genes thought to be critical in the assembly of the OXPHOS complexes [15, 16], also showed downregulation in hypoxia, similar to the effect of Bevacizumab (Fig. 3). However, the majority of the genes downregulated in the arrays failed to exhibit downregulation during hypoxic exposure, suggesting that other factors may

be primarily responsible [17]. Reexamination of the arrays revealed that several transcription factors that regulate mitochondrial gene expression (including OXPHOS) were downregulated: NRF1, TFAM and TFB2M [18–20] (Supplementary Table S3).

Exploitation of the increased glycolytic gap: *in vivo* synergism between Bevacizumab and DCA

Based on the marked signature of increased HIF signaling and decreased mitochondrial OXPHOS we hypothesized that the Bevacizumab-resistant tumors would be particularly sensitive to mitochondrial reactivators. The top small molecule candidate from this class is DCA, which inhibits PDK activity, thereby increasing the flux of pyruvate into the mitochondria, and promoting glucose oxidation over glycolysis [21, 22]. Taking into account the well-recognized side effects of antiangiogenic therapy as well as of DCA, for the assessment of the drug combination we chose a submaximal dose of the antiangiogenic agent (2.5mg/kg; every 3 days by intraperitoneal injection), a strategy which is widely employed *in vivo* [23]. This approach is also anticipated to increase our ability to detect synergism between the two drugs, both from the standpoint of tumor response, and effects on HIF signaling. Indeed, treatment with Bevacizumab and DCA dramatically blocked tumor growth compared to each drug alone (Fig. 4A and Supplementary Fig. S1). In order to assess the generality of the response, we investigated an additional GBM cell type, U118. The response in U118-based grafts was also much more robust with the combination, compared to the individual drugs (Fig. 4B and Supplementary Fig. S1).

The efficacy of glycolytic inhibitors in overcoming resistance to Bevacizumab has been previously proposed [24] without experimental confirmation. DCA and 2-DG were discussed together as part of this concept. However, when 2-DG was tested in parallel to DCA, no additive effect to Bevacizumab was noticed. This was despite the transient effect of 2-DG as a single agent, administered at the concentration described in the literature (Supplementary Fig. S2). Thus, mitochondrial reactivation and direct inhibition of glycolysis have different effects in combination with Bevacizumab.

***In vitro* effects of DCA**

Spheroid models provide a system of intermediate complexity between standard two-dimensional culture systems and tumors *in vivo* because of oxygen and nutrient gradients. Unlike monolayer systems, expanding spheroids mimic the increased avascularity of the *in vivo* structures growing in presence of Bevacizumab. U87 spheroids were generated, as described [25], and grown for 7 days until they reached 0.2 mm³. Spheroids of this size are large enough to allow diffusion of a drug across the spheroid but also are starting to form a small central area of hypoxia and display gradients of nutrients, pH and O₂. Robust divergence of the growth kinetics between DCA-treated and non-treated groups was noticed after 3 days of treatment. This effect was persistent, and from 6 days onwards DCA significantly compromised spheroid expansion (Fig. 4C, D).

Effect of Bevacizumab and DCA combination on HIF targets and histological markers of tumor growth

In order to address whether the effect of the combination on tumor growth was primarily determined by increased cell death or decreased proliferation, we performed histological analyses on these tumors, using well established markers. Necrosis was higher in the treated tumors compared to the untreated ones, but no significant difference was observed between the drugs alone or in combination (Fig. 5). Proliferation rate, as evaluated by quantification of Ki-67 (MIB-1) staining, was significantly lower in the combination group, compared to both untreated and Bevacizumab-only tumors, suggesting that the effect of the combination was predominantly cytostatic (Fig. 5). We then assessed the effects of the drug combination

on HIF signaling, using a combination of immunohistochemistry/quantitative RT-PCR (Fig. 5, 6). Surprisingly, while known to increase oxygen consumption in various experimental systems, DCA alone was not sufficient to measurably increase the expression of the HIF targets *in vivo*. However, in combination with Bevacizumab, CA9 expression increased dramatically in the viable U87 tumor cells. In U118, on the other hand, submaximal Bevacizumab alone led to a dramatic increase in all HIF targets tested, without further measurable increase in the combination treated tumors (Fig. 6 and Supplementary Fig. S3). However, the major caveat is that the tumors surviving in the presence of the combination were dramatically smaller and practically stationary, factors that should mitigate the extent of hypoxia.

DISCUSSION

The main goal of our study was to gain a deeper understanding of tumor adaption to Bevacizumab, by identifying pathways that are associated with resistance, with a particular focus on metabolic responses. We concentrated on a heterotopic rather than an orthotopic model, primarily to ensure the feasibility of monitoring neoplastic growth and escape. Additionally, as subcutaneous tumors reach significantly larger volumes than their orthotopic counterparts, they are arguably more relevant for modeling advanced and hypoxic malignancies.

In a recently published orthotopic model of GBM, increased hypoxia post-Bevacizumab has been reported [24, 26]; however investigating long term growth differences is less feasible in such systems. Despite the “classic” status of tumor metabolism in cancer research and its recent revival, no drug that acts primarily at this level has been approved for routine clinical use [27]. DCA, a small molecule which crosses the blood brain barrier [22], showed promising results in a clinical trial in GBM in combination with surgery, temozolomide and radiation [21], with multiple additional trials currently underway (<http://clinicaltrials.gov/ct2/results?term=+Dichloroacetate>). However, the effect of DCA as a single agent is transient at best, and our tumor models certainly reflect this limitation. A recent study discussed the possibility that Bevacizumab treatment should sensitize tumors to both 2-DG and DCA [24], but these predictions have been confirmed only for DCA in our hands. The lack of a measurable additive or synergistic effect of 2-DG was unlikely due to biological inactivity or inadequate dosing, as it was transiently effective as a single agent. Questions remain as to the mechanism of DCA-mediated tumor inhibition in the presence of Bevacizumab. While DCA was reported to block angiogenesis by itself [21], measurement of mean vessel density (MVD) did not confirm this in our system.

DCA has been shown to exhibit increased cytotoxic effects under hypoxia in a variety of cell lines [28]. The current paradigm is that DCA accelerates oxygen consumption by mitochondrial reactivation and further decreases local oxygen tension [29], thus posing an additional challenge on tumor cells to survive and/or proliferate. Moreover, it has been demonstrated that in cells “hardwired” to selectively utilize glycolysis for ATP generation due to mitochondrial DNA mutations, forced OXPHOS induced by DCA had a toxic effect. DCA also exhibits synergistic cytotoxicity *in vitro* in combination with cisplatin and topotecan, two antineoplastic agents known to damage mitochondrial DNA [30]. One could speculate that the downregulation of mitochondrial genes in the Bevacizumab-resistant tumors represents a form of mitochondrial dysfunction that sensitizes to the effects of DCA.

Interestingly, the effect of DCA, as single agent, on HIF targets in xenografts was subtle at best, despite its well-recognized positive effect on oxygen consumption. In contrast, together with Bevacizumab, DCA led to increased expression of most HIF targets tested in the surviving tumors versus Bevacizumab alone. A possible explanation for these results is that

forced OXPHOS induced by DCA in the presence of very low levels of oxygen, may lead to increased reactive oxygen species production, which in turn may contribute to additional induction of HIF [31]. Additionally, or alternatively, DCA in the presence of Bevacizumab may lead to a further decrease in the local oxygen concentration to levels where the induction of HIF targets becomes more evident by quantitative RT-PCR assay. In addition to increased CA9 expression, enhanced expression of the HIF targets PDK1, 3 and GLUT1 was observed in the tumors surviving in the presence of the drug combination in either U87 or U118 cells. This may reflect a more dramatic “last resort” metabolic shift critical for tumor cell survival. In particular, increased expression of PDK1/3 may be part of a “final attempt” by the tumor cells to counteract in part the effect of DCA and inactivate mitochondrial OXPHOS. Such metabolic shifts in tumors surviving in the presence of Bevacizumab plus DCA may also provide important clues on how to further increase the efficacy of this combination. For example, one could speculate that the resistant tumors may exhibit at least some sensitivity to a further escalation of DCA concentration, although toxicity of this compound may become a limiting factor. Upregulation of tumor-specific carbonic anhydrase CA9 may also play an important role in the survival of the combination-treated tumors, as it accelerates the elimination of excess CO₂ generated from the reactivation of the Krebs cycle [25]. Therefore, CA9 inhibitors which have recently shown promising anticancer effects [32, 33], may be regarded as realistic candidates for a third component of a combination strategy.

In conclusion, molecular dissection of tumor adaptation to anti-VEGF agents may offer valuable clues for building more efficient combinations that include targeting cancer metabolism.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding Source The work was supported by grants from Cancer Research United Kingdom [S.W., A.L.H., H.T., R.L., J.L.], METOXIA p-Medicine European Union Framework 7 [D.S., F.B.], Rhodes Scholar [H.G.], Indiana University Cancer Center startup funds and American Cancer Society [M.I., C.M.D., K.K.].

REFERENCES

1. Cao Y, Arbiser J, D'Amato RJ, D'Amore PA, Ingber DE, Kerbel R, Klagsbrun M, Lim S, Moses MA, Zetter B, Dvorak H, Langer R. Forty-year journey of angiogenesis translational research. *Sci Transl Med*. 2011; 3:114rv113.
2. Wick W, Wick A, Weiler M, Weller M. Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence. *Curr Neurol Neurosci Rep*. 2011; 11:305–312. [PubMed: 21279815]
3. Raizer JJ, Grimm S, Chamberlain MC, Nicholas MK, Chandler JP, Muro K, Dubner S, Rademaker AW, Renfrow J, Bredel M. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. *Cancer*. 2010; 116:5297–5305. [PubMed: 20665891]
4. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. *Nat Rev Cancer*. 2008; 8:592–603. [PubMed: 18650835]
5. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. *J Clin Oncol*. 2009; 27:4733–4740. [PubMed: 19720927]

6. Winter SC, Shah KA, Campo L, Turley H, Leek R, Corbridge RJ, Cox GJ, Harris AL. Relation of erythropoietin and erythropoietin receptor expression to hypoxia and anemia in head and neck squamous cell carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2005; 11:7614–7620. [PubMed: 16278379]
7. Davies S, Dai D, Pickett G, Thiel KW, Korovkina VP, Leslie KK. Effects of bevacizumab in mouse model of endometrial cancer: Defining the molecular basis for resistance. *Oncol Rep*. 2011; 25:855–862. [PubMed: 21240464]
8. Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Gehrs B, Raffeld M, Kinders RJ, Parchment R, Anver MR, Shoemaker RH, Melillo G. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. *Mol Cancer Ther*. 2009; 8:1867–1877. [PubMed: 19584228]
9. Harris RA, Bowker-Kinley MM, Huang B, Wu P. Regulation of the activity of the pyruvate dehydrogenase complex. *Adv Enzyme Regul*. 2002; 42:249–259. [PubMed: 12123719]
10. Wigfield SM, Winter SC, Giatromanolaki A, Taylor J, Koukourakis ML, Harris AL. PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer. *Br J Cancer*. 2008; 98:1975–1984. [PubMed: 18542064]
11. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. *Cell Metab*. 2006; 3:177–185. [PubMed: 16517405]
12. Lu CW, Lin SC, Chen KF, Lai YY, Tsai SJ. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. *J Biol Chem*. 2008; 283:28106–28114. [PubMed: 18718909]
13. Frezza C, Pollard PJ, Gottlieb E. Inborn and acquired metabolic defects in cancer. *J Mol Med (Berl)*. 2011; 89:213–220. [PubMed: 21301796]
14. Rzymiski T, Milani M, Pike L, Buffa F, Mellor HR, Winchester L, Pires I, Hammond E, Ragoussis I, Harris AL. Regulation of autophagy by ATF4 in response to severe hypoxia. *Oncogene*. 2010; 29:4424–4435. [PubMed: 20514020]
15. Prestele M, Vogel F, Reichert AS, Herrmann JM, Ott M. Mrpl36 is important for generation of assembly competent proteins during mitochondrial translation. *Mol Biol Cell*. 2009; 20:2615–2625. [PubMed: 19339279]
16. Emdadul Haque M, Grasso D, Miller C, Spremulli LL, Saada A. The effect of mutated mitochondrial ribosomal proteins S16 and S22 on the assembly of the small and large ribosomal subunits in human mitochondria. *Mitochondrion*. 2008; 8:254–261. [PubMed: 18539099]
17. Tang X, Lucas JE, Chen JL, Lamonte G, Wu J, Wang MC, Koumenis C, Chi JT. Functional Interaction between Responses to Lactic Acidosis and Hypoxia Regulates Genomic Transcriptional Outputs. *Cancer research*. 2012; 72:491–502. [PubMed: 22135092]
18. Scarpulla RC. Nuclear activators and coactivators in mammalian mitochondrial biogenesis. *Biochimica et biophysica acta*. 2002; 1576:1–14. [PubMed: 12031478]
19. Falkenberg M, Gaspari M, Rantanen A, Trifunovic A, Larsson NG, Gustafsson CM. Mitochondrial transcription factors B1 and B2 activate transcription of human mtDNA. *Nat Genet*. 2002; 31:289–294. [PubMed: 12068295]
20. Larsson NG, Barsh GS, Clayton DA. Structure and chromosomal localization of the mouse mitochondrial transcription factor A gene (Tfam). *Mamm Genome*. 1997; 8:139–140. [PubMed: 9060414]
21. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, Maguire C, Gammer TL, Mackey JR, Fulton D, Abdulkarim B, McMurtry MS, Petruk KC. Metabolic modulation of glioblastoma with dichloroacetate. *Sci Transl Med*. 2010; 2:31ra34.
22. Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolictargeting therapy for cancer. *Br J Cancer*. 2008; 99:989–994. [PubMed: 18766181]
23. Pechman KR, Donohoe DL, Bedekar DP, Kurpad SN, Hoffmann RG, Schmainda KM. Characterization of bevacizumab dose response relationship in U87 brain tumors using magnetic resonance imaging measures of enhancing tumor volume and relative cerebral blood volume. *J Neurooncol*. 2011; 105:233–239. [PubMed: 21533524]

24. Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, Thorsen F, Taxt T, Bartos M, Jirik R, Miletic H, Wang J, Stieber D, Stuhr L, Moen I, Rygh CB, Bjerkvig R, Niclou SP. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. *Proceedings of the National Academy of Sciences of the United States of America*. 2011; 108:3749–3754. [PubMed: 21321221]
25. Swietach P, Patiar S, Supuran CT, Harris AL, Vaughan-Jones RD. The role of carbonic anhydrase 9 in regulating extracellular and intracellular pH in three-dimensional tumor cell growths. *J Biol Chem*. 2009; 284:20299–20310. [PubMed: 19458084]
26. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, Conrad CA. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. *Neuro Oncol*. 2010; 12:233–242. [PubMed: 20167811]
27. Kaelin WG Jr, Thompson CB. Q&A: Cancer: clues from cell metabolism. *Nature*. 2010; 465:562–564. [PubMed: 20520704]
28. Anderson KM, Jajeh J, Guinan P, Rubenstein M. In vitro effects of dichloroacetate and CO₂ on hypoxic HeLa cells. *Anticancer Res*. 2009; 29:4579–4588. [PubMed: 20032407]
29. Chen Y, Cairns R, Papandreou I, Koong A, Denko NC. Oxygen consumption can regulate the growth of tumors, a new perspective on the Warburg effect. *PLoS One*. 2009; 4:e7033. [PubMed: 19753307]
30. Stockwin LH, Yu SX, Borgel S, Hancock C, Wolfe TL, Phillips LR, Hollingshead MG, Newton DL. Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC. *Int J Cancer*. 2010; 127:2510–2519. [PubMed: 20533281]
31. Park JH, Kim TY, Jong HS, Kim TY, Chun YS, Park JW, Lee CT, Jung HC, Kim NK, Bang YJ. Gastric epithelial reactive oxygen species prevent normoxic degradation of hypoxia-inducible factor-1α in gastric cancer cells. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2003; 9:433–440. [PubMed: 12538497]
32. Dubois L, Peeters S, Lieuwes NG, Geusens N, Thiry A, Wigfield S, Carta F, McIntyre A, Scozzafava A, Dogne JM, Supuran CT, Harris AL, Masereel B, Lambin P. Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. *Radiother Oncol*. 2011; 99:424–431. [PubMed: 21676479]
33. Morris JC, Chiche J, Grellier C, Lopez M, Bornaghi LF, Maresca A, Supuran CT, Pouyssegur J, Poulsen SA. Targeting hypoxic tumor cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors. *Journal of medicinal chemistry*. 2011; 54:6905–6918. [PubMed: 21851094]

Figure 1.

Analysis of Bevacizumab treated U87-MG tumors. (A) Tumor growth of U87-MG *in vivo*, treated with Bevacizumab (BVC) or vehicle control (CTRL), started from day 12 to the end of the experiment. Mean $\pm$ SE, N=5. **P<0.01. (B) Immunohistochemical staining of tumor sections from CTRL or BVC treated tumors show increased hypoxia using HIF-1 and CA9; and a marker of vessel morphology using CD34. Main images are 10x magnification, and inset images 20x magnification. Sections were stained and scored for (C) Vessel Q (CD31). (D) CA9 levels. (E) Necrosis. Mean $\pm$ SE. *P<0.05; ***P<0.001.

Figure 2.

Gene expression changes in control versus Bevacizumab-treated groups. X-axis represents control and Bevacizumab-treated tumors. Array data were preprocessed using GCRMA, normalized using quantile normalization and log base 2. Expression is shown standardized per gene (Z values; color key at the top). Y-axis: Gene Symbols shown on the right. Blue bands on side indicate mitochondrial gene complexes (from light blue =I to dark blue =V). Green band indicate Krebs cycle genes. Red band indicates HIF targets.

Figure 3. Downregulation of metabolic mitochondrial genes in Bevacizumab-resistant tumors. Quantitative PCR analysis was performed to investigate the effects of BVC treatment or hypoxia on U87 cells. For normoxia versus hypoxia comparisons, cells were incubated at 1% oxygen for 72 hr. The following mitochondrial genes were tested: (A) Mitochondrial ribosomal genes. (B). Krebs cycle enzymes. (C) Electron transport complex I and V components. Gene levels are expressed as fold changes by comparison *in vivo* to PBS controls and *in vitro* to normoxic controls. Mean $\pm$ SE. *P<0.05; **P<0.01; ***P<0.001.

Figure 4.

DCA amplifies the effects of BVC on tumor growth *in vivo*. (A) Tumor growth of U87-MG *in vivo*, treated with either CTRL, BVC, DCA or BVC/DCA, starting from day 7 until the end of the experiment. Mean $\pm$ SE, N=4–6. *P<0.05; (B) Tumor growth of U118 *in vivo*, treated with either CTRL, BVC, DCA or BVC/DCA. The U118 tumors were slow growing and so day 0 is treatment start time. Mean $\pm$ SE, N=4–8. *P<0.05; **P<0.01; (black stars is comparison to CTRL, grey stars to BVC alone); (C) Growth of U87-MG spheroids treated with either vehicle control (CTRL) or 10mM DCA. Spheroids were allowed to grow to 0.2 mm³ before being treated with DCA every 3 days. NB: Error bars are small and within the

symbols. (D) Pictures (at 5x magnification) show representative images of the CTRL and DCA treated spheroids.

Figure 5.

Effect of Bevacizumab and DCA on U87-MG tumor histology. (A) Immunohistochemical staining for CA9, CD31, Ki-67 (MIB-1) and necrosis in FFPE sections of U87-MG tumor xenografts treated with BVC, DCA, a combination of BVC and DCA or vehicle control (CTRL). Quantification of (B) Percentage of the viable tissue positive for CA9; (C) Vessel score, VQ, (CD31); (D) proliferation index, PQ, (Ki-67); (E) Necrosis. All images are shown at 20x magnification. Mean $\pm$ SE. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$.

Figure 6.

Effect of combination therapy of Bevacizumab and DCA on key metabolic genes.

Quantitative PCR analysis was performed to investigate the effects of CTRL, BVC, DCA or BVC/DCA treatment on U87-MG and U118 tumors by measuring fold changes in the RNA (A and B) PDK1 (C and D) CA9. Mean $\pm$ SE, N=4–8. *P<0.05; **P<0.01; ***P<0.001.